Thomas Story Son adds Eli Lilly and Co (LLY) to its portfolio

Eli Lilly and Co (LLY) : Thomas Story Son added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 2,700 shares of Eli Lilly and Co which is valued at $217,512 , the company said in a statement filed on Aug 8, 2016 with the SEC.Eli Lilly and Co makes up approximately 0.13% of Thomas Story Son’s portfolio.

Other Hedge Funds, Including , Rand Wealth boosted its stake in LLY in the latest quarter, The investment management firm added 396 additional shares and now holds a total of 8,796 shares of Eli Lilly and Co which is valued at $717,402. Eli Lilly and Co makes up approx 0.09% of Rand Wealth’s portfolio.Goelzer Investment Management reduced its stake in LLY by selling 126 shares or 0.48% in the most recent quarter. The Hedge Fund company now holds 26,053 shares of LLY which is valued at $2,125,664. Eli Lilly and Co makes up approx 0.28% of Goelzer Investment Management’s portfolio.First National Bank Of Mount Dora Trust Investment Services reduced its stake in LLY by selling 450 shares or 1.86% in the most recent quarter. The Hedge Fund company now holds 23,724 shares of LLY which is valued at $1,904,563. Eli Lilly and Co makes up approx 1.05% of First National Bank Of Mount Dora Trust Investment Services’s portfolio.Acropolis Investment Management reduced its stake in LLY by selling 350 shares or 12.14% in the most recent quarter. The Hedge Fund company now holds 2,532 shares of LLY which is valued at $202,433. Eli Lilly and Co makes up approx 0.04% of Acropolis Investment Management’s portfolio.

Eli Lilly and Co opened for trading at $80.33 and hit $80.62 on the upside on Monday, eventually ending the session at $80.26, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 27,80,381 shares. Company has a market cap of $88,594 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *